Clinical trials: immunohistochemistry staining method, completed
Unspecified Childhood Solid Tumor, Protocol Specific
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children and adolescents with…
- Trial name
- NCT00985868
- Testing
- multikinase inhibitor AT9283, enzyme-linked immunosorbent assay, immunohistochemistry staining method
- Where
- 5 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- Cancer Research UK
Breast Cancer
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00482755
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- NCIC Clinical Trials Group
Esophageal Cancer
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00524121
- Testing
- erlotinib hydrochloride, immunohistochemistry staining method, radiation therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working.
- Trial name
- NCT00897702
- Testing
- Blood draw, immunoenzyme technique, biopsy
- Where
- 7 sites in United States
- Volunteers
- 269 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer Recurrent
Identification of Predictive Biomarkers
Molecular nuclear imaging in prostate cancer has made significant progress in the last few years. The introduction of tracers that target the prostate-specific membrane antigen (PSMA) has profoundly influenced imaging diagnostics…
- Trial name
- BioPoP (NCT04324983)
- Testing
- Blood sample
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Martini-Klinik am UKE GmbH
Endometrial Cancer
Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy.
- Trial name
- NCT06148129
- Testing
- Tissue Biopsy
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Zagazig University
Lymphoma
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients…
- Trial name
- NCT00561756
- Testing
- plasmid DNA vaccine therapy, flow cytometry, immunoenzyme technique
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High-Grade Squamous Intraepithelial Lesions
Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions
Lesions classified as "High Grade Squamous Intra-epithelial Lesions" (HSIL) are pre-cervical lesions of the cervix, induced by infection with the Human Papilloma Virus (HPV).
- Trial name
- NCT03920800
- Testing
- Data extraction from medical files, Immunohistochemistry
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Catherine Vanpachterbeke
Immune Thrombocytopenic Purpura, Splenectomy; Status
Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura
The aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with ITP who had a splenectomy to treat their ITP(Immune…
- Trial name
- SPLENOTIR (NCT04056507)
- Testing
- Immunolabeling
- Volunteers
- 80 people
- Sponsor
- University Hospital, Bordeaux
Nasopharyngeal Carcinoma (NPC)
Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy
Clinicopathological and genomic data (Next generation sequencing and IHC/CISH) in available tissues were performed in patients with nasopharyngeal carcinoma who participated in a previously conducted randomized phase II study…
- Trial name
- NCT07741110
- Testing
- Next generation sequencing, Immunohistochemistry/CISH
- Volunteers
- 141 people
- Sponsor
- Hellenic Cooperative Oncology Group
Stage IV Pancreatic Cancer
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
The Investigators in the PCRT team have developed a therapeutic regimen which attacks both the tumor compartment and the stromal compartment of pancreatic cancer and induces complete responses in a small percentage of patients…
- Trial name
- NCT01488552
- Testing
- Gemcitabine, nab-paclitaxel, FOLFIRINOX
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Cancer
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900016
- Testing
- protein expression analysis, western blotting, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fox Chase Cancer Center
Kidney Cancer
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
RATIONALE: Studying samples of tissue and urine from patients with cancer in the laboratory may help doctor learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01542333
- Testing
- gene expression analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
Pulmonary Embolism
Pulmonary Embolism: an Autopsy Study
BACKGROUND: Pulmonary embolism (PE) is associated to high mortality rate worldwide. However, the diagnosis of PE often results inaccurate.
- Trial name
- NCT03887819
- Testing
- Hystological evaluation
- Volunteers
- 15 people
- Sponsor
- University of Campania Luigi Vanvitelli
Breast Cancer
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499083
- Testing
- therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Colorectal Cancer
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00466505
- Testing
- cetuximab, celecoxib, proteomic profiling
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
RATIONALE: Giving thalidomide together with prednisone and cyclophosphamide may lessen symptoms caused by myelofibrosis and myeloid metaplasia.
- Trial name
- NCT00445900
- Testing
- cyclophosphamide, prednisone, thalidomide
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Primary Soft-tissue Sarcoma
A Microdose Evaluation Study of ABY-029 in Primary Sarcoma
The primary study objective is to determine if microdoses of ABY-029 (up to 6X) lead to detectable signals (defined as signal-to-noise ratio, SNR ≥10, with the Odyssey NIR scanner in sampled tissues with an EGFR pathology score ≥…
- Trial name
- NCT03154411
- Testing
- ABY-029
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372736
- Testing
- AEG35156, docetaxel, protein expression analysis
- Where
- 3 sites in Canada
- Volunteers
- 27 people
- Sponsor
- NCIC Clinical Trials Group